Study design: In this comparative descriptive study 30 patients suffering from rheumatoid arthritis (RA) received either methotrexate (MTX), sulfasalazine (SSZ) or MTX plus SSZ for 2 years to evaluate the outcome of these therapies by measuring the change in DAS28 score.

Results: The DAS28 score was lowered significantly in all three administration regimens. The statistically significant reduction in patients treated with combination therapy group was highest.

Conclusions: Co-administration of MTX and SSZ results in a better DAS28 score than administration of MTX or SSZ alone, recommending a combination therapy for RA patients.